The Collision of Innovation And Access In US Healthcare
This article was originally published in RPM Report
The RPM Report’s FDA/CMS Summit for Biopharma Executives included sessions devoted to many issues that impact the biopharma industry and patient care. They raised essential questions about public policy and biopharma. But all are part of a much bigger question: How do we create and sustain real value in our healthcare system?